@article{04dc4a9383a9438abf9b31f97177f91b,
title = "Nivolumab plus ipilimumab in non-small-cell lung cancer",
author = "Juwon Kim and Shin, {Sang W.}",
note = "Funding Information: Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = feb,
day = "27",
doi = "10.1056/NEJMc1916859",
language = "English",
volume = "382",
pages = "874",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",
}
